title: Modulation of dendritic cell and monocyte subsets in tuberculosis-diabetes co-morbidity upon standard tuberculosis treatment.
abstract: Type 2 diabetes mellitus (DM) is a major risk factor for the development of active pulmonary tuberculosis (PTB), with development of DM pandemic in countries where tuberculosis (TB) is also endemic. However, the effect of anti-TB treatment on the changes in dentritic cell (DC) and monocyte subset phenotype in TB-DM co-morbidity is not well understood. In this study, we characterized the frequency of DC and monocyte subsets in individuals with PTB with (PTB-DM) or without coincident diabetes mellitus (PTB-NDM) before, during and after completion of anti-TB treatment. PTB-DM is characterized by diminished frequencies of plasmacytoid and myeloid DCs and classical and intermediate monocytes at baseline and 2 months of anti-TB treatment but not following 6 months of treatment completion in comparison to PTB-NDM. DC and monocyte subsets exhibit significant but borderline correlation with fasting blood glucose and glycated hemoglobin levels. Finally, while minor changes in the DC and monocyte compartment were observed at 2 months of treatment, significantly increased frequencies of plasmacytoid and myeloid DCs and classical and intermediate monocytes were observed at the successful completion of anti-TB treatment. Our data show that coincident diabetes alters the frequencies of innate subset distribution of DC and monocytes in TB-DM co-morbidity and suggests that most of these changes are reversible following anti-TB therapy.
authors.affiliation: National Institutes of Health-NIRT- International Center for Excellence in Research, Chennai, India. Electronic address: pavankumarn@nirt.res.in.
authors.forename: Nathella Pavan
authors.initials: NP
authors.lastname: Kumar
authors.affiliation: National Institutes of Health-NIRT- International Center for Excellence in Research, Chennai, India.
authors.forename: Kadar
authors.initials: K
authors.lastname: Moideen
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: Shanmugam
authors.initials: S
authors.lastname: Sivakumar
authors.affiliation: National Institute for Research in Tuberculosis, Chennai, India.
authors.forename: Pradeep A
authors.initials: PA
authors.lastname: Menon
authors.affiliation: Prof. M. Viswanathan Diabetes Research Center, Chennai, India.
authors.forename: Vijay
authors.initials: V
authors.lastname: Viswanathan
authors.affiliation: University of Massachusetts Medical School, Worcester, MA, USA.
authors.forename: Hardy
authors.initials: H
authors.lastname: Kornfeld
authors.affiliation: National Institutes of Health-NIRT- International Center for Excellence in Research, Chennai, India; LPD, NIAID, NIH, MD, USA.
authors.forename: Subash
authors.initials: S
authors.lastname: Babu
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002478:Cells, Cultured; D015897:Comorbidity; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000276:immunology*; D005260:Female; D006801:Humans; D006943:Hyperglycemia / Q000453:epidemiology / Q000276:immunology; D016130:Immunophenotyping; D007194:India / Q000453:epidemiology; D008297:Male; D009000:Monocytes / Q000187:drug effects* / Q000276:immunology; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D013183:Sputum / Q000382:microbiology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents